NAS
PVLA

Nykredit A/S’s Palvella Therapeutics PVLA Stock Holding History

Nykredit A/S’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.2K Buy
+139
New +$16.9K ﹤0.01% 1721

Other funds holding PVLA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Nykredit A/S's PVLA Position: Q2 2026 in Review

Nykredit A/S opened a new position in Palvella Therapeutics (PVLA) in Q2 2026: 139 shares worth $21.2K. The stake represents ﹤0.01% of the portfolio and ranks #1721 among its holdings.

127 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Nykredit A/S held 139 shares of Palvella Therapeutics worth $21.2K as of Q2 2026.
  • Palvella Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Palvella Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1721 holding.
  • 127 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.